Health Catalyst, Inc. (NASDAQ:HCAT) Insider Linda Llewelyn Sells 6,442 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) insider Linda Llewelyn sold 6,442 shares of Health Catalyst stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $7.88, for a total value of $50,762.96. Following the sale, the insider now owns 98,702 shares in the company, valued at $777,771.76. This represents a 6.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Linda Llewelyn also recently made the following trade(s):

• On Tuesday, October 15th, Linda Llewelyn sold 1,324 shares of Health Catalyst stock. The shares were sold at an average price of $8.16, for a total transaction of $10,803.84.

Health Catalyst Stock Up 1.7 %

Health Catalyst stock opened at $7.09 on Friday. The firm has a 50 day moving average price of $8.11 and a two-hundred day moving average price of $7.45. Health Catalyst, Inc. has a 52-week low of $5.42 and a 52-week high of $11.41. The firm has a market cap of $431.41 million, a price-to-earnings ratio of -5.25 and a beta of 1.31. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.22) EPS. Equities analysts predict that Health Catalyst, Inc. will post -0.33 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC lifted its stake in Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock valued at $25,279,000 after purchasing an additional 3,221,408 shares during the last quarter. Millennium Management LLC raised its stake in shares of Health Catalyst by 96.3% in the second quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares during the period. Nepsis Inc. lifted its position in shares of Health Catalyst by 67.9% during the 3rd quarter. Nepsis Inc. now owns 2,104,528 shares of the company’s stock valued at $17,131,000 after buying an additional 851,448 shares during the last quarter. Fred Alger Management LLC bought a new position in shares of Health Catalyst during the 3rd quarter worth $6,858,000. Finally, Portolan Capital Management LLC purchased a new stake in Health Catalyst in the 3rd quarter worth about $5,402,000. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HCAT has been the topic of a number of research analyst reports. Royal Bank of Canada boosted their target price on Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a report on Thursday, November 7th. Piper Sandler restated an “overweight” rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. JPMorgan Chase & Co. upped their price objective on shares of Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a report on Wednesday, September 4th. Evercore ISI upped their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research report on Tuesday, October 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.79.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.